(Q44625738)

4 December 2017

title

Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients (English)

1 reference

4 December 2017

Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 12-month study in 208 patients (English)

1 reference

https://api.crossref.org/works/10.1177/153331750301800508

23 March 2024

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14569643

23 March 2024

author name string

Rita Moretti

1

1 reference

4 December 2017

Paola Torre

2

1 reference

4 December 2017

Giuseppe Cazzato

4

1 reference

4 December 2017

Antonio Bava

5

1 reference

4 December 2017

Rodolfo M. Antonello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14569643

23 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

http://journals.sagepub.com/doi/pdf/10.1177/153331750301800508

1 reference

https://api.crossref.org/works/10.1177/153331750301800508

American Journal of Alzheimer's Disease & Other Dementias

23 March 2024

published in

1 reference

4 December 2017

volume

18

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

265-272

1 reference

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Frontal-subcortical circuits and human behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Neuropsychological aspects of vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Differentiation of vascular dementia from AD on neuropsychological tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

A new clinical scale for the staging of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Development and validation of a geriatric depression screening scale: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Validation of a measure of physical illness burden at autopsy: the Cumulative Illness Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

European Pentoxifylline Multi-Infarct Dementia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750301800508

Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats.

21 January 2018

9

1 reference

https://api.crossref.org/works/10.1177/153331750301800508

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

23 March 2024

32

1 reference

https://api.crossref.org/works/10.1177/153331750301800508

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

23 March 2024

47

1 reference

https://api.crossref.org/works/10.1177/153331750301800508

23 March 2024

Identifiers

1 reference

4 December 2017

1 reference